Caskey, Marina

Publications

Sort by

Co-Author Network

selected publications

Broadly Neutralizing Antihuman Immunodeficiency Virus Antibodies in Infants: Promising New Tools for Prevention of Mother-to-Child Transmission?. The Journal of infectious diseases. 2020 Editorial Article GET IT
Times cited: 1
Broadly neutralizing antibodies for the treatment and prevention of HIV infection. Current opinion in HIV and AIDS. 2020 Review GET IT
Times cited: 32
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PloS one. 2019 Academic Article GET IT
Times cited: 43
Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. The Journal of experimental medicine. 2019 Academic Article GET IT
Times cited: 57
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nature medicine. 2019 Review GET IT
Times cited: 150
Delivery of anti-HIV bNAbs by viral vectors. The lancet. HIV. 2019 Comment GET IT
Times cited: 4
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. The lancet. HIV. 2019 Conference Paper GET IT
Times cited: 116
Relationship between intact HIV-1 proviruses in circulating CD4⁺ T cells and rebound viruses emerging during treatment interruption. Proceedings of the National Academy of Sciences of the United States of America. 2018 Academic Article GET IT
Times cited: 49
Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018 Academic Article GET IT
Times cited: 300
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nature medicine. 2018 Academic Article GET IT
Times cited: 159
Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. The Journal of experimental medicine. 2018 Academic Article GET IT
Times cited: 68
Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection. Current opinion in HIV and AIDS. 2018 Review GET IT
Times cited: 58
Clonal CD4⁺ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation. Nature medicine. 2018 Academic Article GET IT
Times cited: 83
Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. Journal of virology. 2018 Academic Article GET IT
Times cited: 32
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. Cell. 2017 Academic Article GET IT
Times cited: 214
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nature medicine. 2017 Academic Article GET IT
Times cited: 314
Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. Proceedings of the National Academy of Sciences of the United States of America. 2016 Academic Article GET IT
Times cited: 309
Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy. The New England journal of medicine. 2016 Academic Article GET IT
Times cited: 52
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016 Academic Article GET IT
Times cited: 329
Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science (New York, N.Y.). 2016 Academic Article GET IT
Times cited: 254
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science (New York, N.Y.). 2016 Academic Article GET IT
Times cited: 221
Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2016 Academic Article GET IT
Times cited: 2
A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract. Mucosal immunology. 2016 Academic Article GET IT
Times cited: 19
Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone marrow transplantation. 2015 Academic Article GET IT
Times cited: 63
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015 Academic Article GET IT
Times cited: 557
Circulating precursors of human CD1c+ and CD141+ dendritic cells. The Journal of experimental medicine. 2015 Academic Article GET IT
Times cited: 161
HIV-1 integration landscape during latent and active infection. Cell. 2015 Academic Article GET IT
Times cited: 296
A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. Journal of acquired immune deficiency syndromes (1999). 2014 Academic Article GET IT
Times cited: 61
Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. Journal of internal medicine. 2012 Review GET IT
Times cited: 131
Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. The Journal of experimental medicine. 2011 Academic Article GET IT
Times cited: 221
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PloS one. 2011 Academic Article GET IT
Times cited: 150
Clinical manifestations in individuals with recent diagnosis of HTLV type I infection. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2011 Academic Article GET IT
Times cited: 46
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PloS one. 2010 Academic Article GET IT
Times cited: 55
Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. The Journal of experimental medicine. 2009 Academic Article GET IT
Times cited: 500
The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proceedings of the National Academy of Sciences of the United States of America. 2008 Academic Article GET IT
Times cited: 250
Brain magnetic resonance imaging white matter lesions are frequent in HTLV-I carriers and do not discriminate from HAM/TSP. AIDS research and human retroviruses. 2007 Academic Article GET IT
Times cited: 41
Clinical manifestations associated with HTLV type I infection: a cross-sectional study. AIDS research and human retroviruses. 2007 Academic Article GET IT
Times cited: 62
Childhood and adolescent growth of patients with sickle cell disease in Aracaju, Sergipe, north-east Brazil. Annals of tropical paediatrics. 2000 Academic Article GET IT
Times cited: 14

more ...

less ...

Background

education and training

M.S., The Rockefeller University 2009
M.D., University Federal de Sergipe Medical Faculty (Brazil) 1998

Contact

full name

Marina Caskey

primary email

mac9097@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Marina Caskey Adjunct Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage